These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30249879)

  • 21. Liver Abscess Formation Following Transarterial Chemoembolization: Clinical Features, Risk Factors, Bacteria Spectrum, and Percutaneous Catheter Drainage.
    Lv WF; Lu D; He YS; Xiao JK; Zhou CZ; Cheng DL
    Medicine (Baltimore); 2016 Apr; 95(17):e3503. PubMed ID: 27124055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Lee JS; Chon YE; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kang W; Choi MS; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Kim HY; Kim TH; Yoo K; Ha Y; Kim MN; Lee JH; Hwang SG; Kim SS; Cho HJ; Cheong JY; Cho SW; Park SH; Heo NY; Hong YM; Yoon KT; Cho M; Park JG; Kang MK; Park SY; Kweon YO; Tak WY; Jang SY; Sinn DH; Kim SU;
    Yonsei Med J; 2021 Jan; 62(1):12-20. PubMed ID: 33381930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization.
    Shin BS; Park MH; Jeon GS
    Acta Radiol; 2011 Apr; 52(3):331-5. PubMed ID: 21498371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive Factors of Tumor Recurrence and Survival in Patients with Hepatocellular Carcinoma treated with Transarterial Chemoembolization.
    Cerban R; Ester C; Iacob S; Grasu M; Pâslaru L; Dumitru R; Lupescu I; Constantin G; Croitoru A; Gheorghe L
    J Gastrointestin Liver Dis; 2018 Dec; 27(4):409-417. PubMed ID: 30574623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and microbiological features of liver abscess after transarterial embolization for hepatocellular carcinoma.
    Chen C; Chen PJ; Yang PM; Huang GT; Lai MY; Tsang YM; Chen DS
    Am J Gastroenterol; 1997 Dec; 92(12):2257-9. PubMed ID: 9399765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma.
    Oliveri RS; Wetterslev J; Gluud C
    Cochrane Database Syst Rev; 2011 Mar; (3):CD004787. PubMed ID: 21412886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
    Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Palliative treatment of unresectable hepatocellular carcinoma with obstructive jaundice using biliary drainage with subsequent transarterial chemoembolization.
    Choi J; Ryu JK; Lee SH; Hwang JH; Ahn DW; Kim YT; Yoon YB; Yoon CJ; Kang SG; Chung JW
    J Palliat Med; 2013 Sep; 16(9):1026-33. PubMed ID: 23888306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis.
    Siriwardana RC; Niriella MA; Dassanayake AS; Liyanage CA; Upasena A; Sirigampala C; de Silva HJ
    BMC Gastroenterol; 2015 Aug; 15():96. PubMed ID: 26239844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma.
    Li JH; Xie XY; Zhang L; Le F; Ge NL; Li LX; Gan YH; Chen Y; Zhang JB; Xue TC; Chen RX; Xia JL; Zhang BH; Ye SL; Wang YH; Ren ZG
    World J Gastroenterol; 2015 Apr; 21(13):3970-7. PubMed ID: 25852283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation.
    Kluger MD; Halazun KJ; Barroso RT; Fox AN; Olsen SK; Madoff DC; Siegel AB; Weintraub JL; Sussman J; Brown RS; Cherqui D; Emond JC
    Liver Transpl; 2014 May; 20(5):536-43. PubMed ID: 24493271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Sapir E; Tao Y; Schipper MJ; Bazzi L; Novelli PM; Devlin P; Owen D; Cuneo KC; Lawrence TS; Parikh ND; Feng M
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):122-130. PubMed ID: 29066120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization.
    Baek MY; Yoo JJ; Jeong SW; Jang JY; Kim YK; Jeong SO; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim YJ; Park SY
    Korean J Intern Med; 2019 Nov; 34(6):1223-1232. PubMed ID: 30360019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence, risk factors, and prognosis of acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma: a prospective cohort study.
    Hao JF; Zhang LW; Bai JX; Li YJ; Liu JN; Zhang XL; Han JM; Li X; Jiang H; Cao N
    Indian J Cancer; 2015 Feb; 51 Suppl 2():e3-8. PubMed ID: 25712839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effect of Transarterial Chemoembolization in Combination With Kang'ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study.
    Wan YM; Li YH; Xu ZY; Wu HM; Xu Y; Yang M; Wu XN
    Integr Cancer Ther; 2018 Jun; 17(2):477-485. PubMed ID: 29108428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.